🇺🇸 FDA
Pipeline program

LEE011

CLEE011A2115C

Phase 1 small_molecule completed

Quick answer

LEE011 for Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials